$750 Million Market on Track to $3.35 Billion by 2034: $NRXP Launches First-in-Florida "One Day" Depression Treatment in Partnership with Ampa Health
Wisconsin Eagle/10322728

MIAMI - WisconsinEagle -- NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP), a clinical-stage biopharmaceutical innovator developing breakthrough therapeutics for central nervous system disorders, has emerged as a potential leader in the next generation of psychiatric care. With the global ketamine market projected to expand from $750 million to $3.35 billion by 2034, NRXP is strategically positioned to capture a substantial share through a suite of FDA-designated and investigational treatments aimed at addressing urgent mental health needs.

Revolutionary "ONE-D" Depression Treatment Launches in Florida

NRx recently announced the first-in-Florida launch of its "One Day" (ONE-D) depression treatment, developed in partnership with Ampa Health. The ONE-D protocol uses Ampa's advanced Transcranial Magnetic Stimulation (TMS) device — the first reported technology capable of achieving remission from treatment-resistant depression in a single day.

Unlike conventional 90-day TMS regimens, the ONE-D treatment integrates a single day of precision TMS with D-cycloserine and lisdexamfetamine (both utilized under physician supervision), achieving up to 87% response and 72% remission rates in peer-reviewed nonrandomized studies.

The technology is initially deployed at multiple NRXP HOPE Clinics in Sarasota, Naples, and Fort Myers, with expansion to six Florida locations by year-end 2025 under the direction of Dr. Rebecca Cohen, Medical Director of HOPE Clinics.

More on Wisconsin Eagle

• From Cheer to Courtroom: The Hidden Legal Risks in Your Holiday Eggnog
• Controversial Vegan Turns Rapper Launches First Song, "Psychopathic Tendencies."
• Inside the Fight for Affordable Housing: Avery Headley Joins Terran Lamp for a Candid Bronx Leadership Conversation
• Canterbury Hotel Group Announces the Opening of the TownePlace Suites by Marriott Portland Airport
• Heritage at South Brunswick's Resort-Style Amenities for Any Age and Every Lifestyle

NRX-101: A Breakthrough Therapy for Suicidal Bipolar Depression

Central to NRx's pipeline is NRX-101, an FDA-designated Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. The therapy leverages the company's proprietary NMDA platform and is being developed in partnership with Alvogen Pharmaceuticals.

NRX-101 also holds potential as a non-opioid pain treatment and for other indications such as complicated urinary tract infections (UTIs). With over 13 million Americans seriously considering suicide each year (CDC), NRXP's drug candidates could address one of the nation's most pressing health crises.

KETAFREE™: FDA-Focused Push to Modernize Ketamine Treatment

NRXP recently re-filed its Abbreviated New Drug Application (ANDA) for KETAFREE™, a preservative-free IV ketamine formulation, after securing FDA approval of its Suitability Petition. By eliminating benzethonium chloride (BZT) — a preservative linked to neurotoxicity — KETAFREE™ represents a safer, next-generation alternative to traditional ketamine products.

The company has also petitioned the FDA to formally remove BZT from IV formulations, citing expert toxicological data and the growing demand for preservative-free therapies in modern medicine. Given the ongoing ketamine shortage reported by the American Society of Hospital Pharmacists, NRXP's KETAFREE™ could fill a critical supply gap and strengthen its market positioning.

Strategic Acquisitions and Growth Initiatives

NRXP recently completed the acquisition of Dura Medical, an EBITDA-positive network of interventional psychiatry clinics delivering advanced therapies for depression and PTSD. This acquisition, along with pending deals for Neurospa TMS and Cohen & Associates, expands NRXP's reach to more than eight Florida clinic locations, reinforcing its vertically integrated mental health care model.

More on Wisconsin Eagle

• T-TECH Partners with Japan USA Precision Tools for 2026 US Market Development of the New T-TECH 5-Axis QUICK MILL™
• Record Revenues, Debt-Free Momentum & Shareholder Dividend Ignite Investor Attention Ahead of 2026–2027 Growth Targets: IQSTEL (N A S D A Q: IQST)
• New YouTube Channel Pair Launches to Bring Entertainment Nostalgia Back to Life
• BRAG Hosts Holiday Benefit — Awards 10 Student Scholarships & Honors Timberland with the Corporate Impact Award
• FittingPros Launches Industry's First Data-Driven Golf Club Fitting Directory

To accelerate this rollout, NRXP secured $7.8 million in debt financing from Universal Capital, LLC to fund further HOPE Clinic acquisitions.

Additionally, NRXP has accepted non-binding licensing terms for NRX-100, a drug candidate expected to generate over $300 million in potential milestone payments and tiered double-digit royalties upon commercialization.

Strong Analyst Endorsement

In a recently released report, D. Boral Research issued a Buy rating on NRXP with a $34 price target, citing the company's expanding clinical pipeline, growing footprint in the interventional psychiatry sector, and first-mover advantage in the transformative ONE-D treatment platform.

A Vision for Transforming Mental Health

From its FDA Fast Track designation for IV ketamine (NRX-100) to its breakthrough therapy designation for NRX-101, NRx Pharmaceuticals continues to redefine the boundaries of psychiatric medicine. Its commitment to science-driven innovation — now coupled with real-world clinic deployment through HOPE Clinics — positions NRXP as both a therapeutic pioneer and a potentially lucrative opportunity in the rapidly expanding mental health market.

Company Contact:
NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP)
📍 Wilmington, DE
Matthew Duffy, Chief Business Officer
📧 mduffy@nrxpharma.com | ☎️ (484) 254-6134
🌐 www.nrxpharma.com

DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website